GlobeNewswire
-
InSitu Biologics Announces Completion of INSB200™ GMP Manufacturing Batch
19/11/2026 -
Koç Healthcare Calls for Clearer Travel Insurance Cover at ITIC Global 2026 and Highlights New Ground Ambulance Services
19/11/2026 -
NEXGEL Postpones Third Quarter 2026 Financial Results and Corporate Update Conference Call to November 24th
19/11/2026 -
Cingulate Announces U.S. Patent Issuance for CTx-2103, Further Validating PTR™ Technology Platform
19/11/2026 -
Acentra Health CEO Todd Stottlemyer Named 2026 Virginia Business Icon Honoree
19/11/2026 -
Hennick Humber Hospital Foundation’s Big Bash for Humber Raises $3.9 Million NET to Bring Life-Saving Cardiac Care Closer to Home
19/11/2026 -
The Silk Road Gets a Spidey Genetic Upgrade
19/11/2026 -
Sienna Senior Living Introduces Virtual Primary Care Benefit for Employees and Their Families
19/11/2026 -
Researchify Health Announces Five-Year Plan to Engage 100 Million Patients Each Month About Clinical Trials
19/11/2026 -
A Race Against Blindness Brings Back “Miles, Magic & Mochas” Fundraiser for the Holiday Season
19/11/2026 -
HUTCHMED Announces China NMPA Approval of SYVIK® (sovleplenib) for the Treatment of Primary Immune Thrombocytopenia and Warm Antibody Autoimmune Hemolytic Anemia
19/11/2026 -
Codexis to Participate in Piper Sandler 38th Annual Healthcare Conference
19/11/2026 -
Zymeworks Announces Participation in Upcoming Investor Conferences
19/11/2026 -
EBI Reaches Key Milestone with First Patient Enrolled in Phase III EasyBoost Trial of EA-230, a Potential First-in-Class Medicine to Accelerate Recovery After Cardiac Surgery
19/11/2026 -
CDT Notes Sarborg’s Sale of Cryptocurrency Trading Agent
19/11/2026 -
ANI Pharmaceuticals to Present at Upcoming December Investor Conference
19/11/2026 -
Regeneron Highlights New Data Across Malignant and Classical Hematology Programs at American Society of Hematology (ASH)
19/11/2026 -
aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting
19/11/2026 -
Remix Therapeutics Announces Updated Positive REM-422 Phase 1 Data in Adenoid Cystic Carcinoma at 2026 EORTC-NCI-AACR Symposium
19/11/2026
Pages